Presentation and progression of MPO-ANCA interstitial lung disease.

Autor:	Salvati L; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Palterer B; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Lazzeri E; Department of Clinical and Experimental Biomedical Sciences, Excellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence, Italy., Vivarelli E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Amendola M; Pneumology and Intensive Care Unit, Careggi University Hospital, Florence, Italy., Allinovi M; Nephrology Unit, Careggi University Hospital, Florence, Italy., Caroti L; Nephrology Unit, Careggi University Hospital, Florence, Italy., Mazzoni A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, Florence, Italy., Lasagni L; Department of Clinical and Experimental Biomedical Sciences, Excellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), University of Florence, Florence, Italy., Emmi G; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Cavigli E; Department of Emergency Radiology, Careggi University Hospital, Florence, Italy., Del Carria M; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Di Pietro L; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Scavone M; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Cammelli D; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Lavorini F; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; Pneumology and Intensive Care Unit, Careggi University Hospital, Florence, Italy., Tomassetti S; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; Interventional Pulmonology Unit, Careggi University Hospital, Florence, Italy., Rosi E; Pneumology and Intensive Care Unit, Careggi University Hospital, Florence, Italy., Parronchi P; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy.
Jazyk:	angličtina
Zdroj:	Journal of translational autoimmunity [J Transl Autoimmun] 2024 Feb 23; Vol. 8, pp. 100235. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
DOI:	10.1016/j.jtauto.2024.100235
Abstrakt:	The association between MPO-ANCA-associated vasculitis (AAV) and interstitial lung disease (ILD) has been well established. Pulmonary fibrosis may coexist with, follow, or even precede the diagnosis of AAV, and its presence adversely affects the prognosis. The optimal approach to investigating ANCA in patients with ILD remains a subject of ongoing debate. Here we aim to describe presentation and progression of MPO-ANCA ILD. We conducted a retrospective evaluation of a cohort of individuals diagnosed with MPO-ANCA ILD, with or without accompanying renal impairment, at the Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy, between June 2016 and June 2022. Clinical records, imaging studies, pathologic examinations, and laboratory test results were collected. Among the 14 patients identified with MPO-ANCA ILD, we observed a significant association between MPO-ANCA titers assessed at the time of ILD diagnosis and renal involvement. Renal impairment in these cases often manifested as subclinical or slowly progressive kidney damage. Interestingly, complement C3 deposits were consistently found in all renal biopsy specimens, thereby suggesting the potential for novel therapeutic targets in managing renal complications associated with MPO-ANCA ILD. The presentation of MPO-ANCA vasculitis as ILD can be the first and only clinical manifestation. MPO-ANCA levels at ILD diagnosis could warn on the progression to renal involvement in patients with MPO-ANCA ILD, hence caution is needed because renal disease can be subclinical or smoldering. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu